الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
HCC is a major cause of morbidity and mortality; it is the seventh most common cancer world-wide, and the third leading cause of cancer related deaths. Its prognosis is poor and early detection is of great importance.
AFP is the currently available traditional marker for the detection of hepatocellular carcinoma. Its poor sensitivity renders it unsatisfactory for this purpose and suggests an urgent need for novel biomarkers for early stage HCC detection.
Talin-1 is identified cytoplasmic protein partner of integrins that is important component of focal adhesion complexes of adherent cells.Talin-1 has been identified as a novel molecular marker for HCC progression and has revealed that its up regulation is associated with HCC progression showing that it may serve as a prognostic marker.
The present study directed towards evaluation the role of serum Talin-1 as a novel biomarker for the diagnosis of HCC and comparison between this marker and the traditional marker AFP.
This study was conducted in Clinical Pathology Department, National Liver Institute, Menoufia University.
The study included 87 subjects classified into three groups. Group (I): included 22 patients with liver cirrhosis, (18) males and (4) females. Group (II): included 43 patients with hepatocellular carcinoma as diagnosed by triphasic CT, (32) males and (11) females. Group (III): Included 22 apparently healthy volunteers age and gender matched with the diseased groups served as control, (12) males and (10) females.
Summary
103
All patients and controls were subjected to thorough history taking, full general clinical examinations, abdominal ultrasonography, Triphasic CT abdomen to diagnose hepatocellular carcinoma, Liver
function tests, HCV antibody, HBsAg, AFP and serum Talin-1 by enzyme linked immune-sorbent assay (ELISA).
The results of this study revealed that:
As regard age and gender, there were no significant diffrence between the studied groups.
There were highly significant statistical difference between the studied groups as regard (ALT, AST, AST/ALT, ALP, γGT, total bilirubin, direct bilirubin, albumin and total protein) (P< 0.001).
As regard AFP level, the highest level was observed among HCC group, followed by cirrhosis group, and the lowest level observed among control group.
There was a statistically significant increase in serum Talin-1 levels in patient groups as compared to control group.
The highest level was observed among HCC group, followed by cirrhosis group, and the lowest level observed among control group.
Serum Talin-l in HCC patients positively correlated with tumor size, and presence of ascites in HCC patients.
Serum Talin 1 level has higher sensitivity in prediction of HCC than AFP level so; it has a better diagnostic value in diagnosis of HCC.
Measuring both serum Talin 1 and AFP levels enhance the diagnostic sensitivity in early diagnosis of HCC.